TAT peptides can get into the nucleus of the cell, but only at higher concentrations than what Phylogica's CPPs have been able to achieve. The reason is because of what was highlighted on slide 11 of the presentation below i.e. superior delivery. As a result there'd be more toxicity present throughout the body, due to the non-specific cell CPPs, but also the higher concentrations, which would also mean higher costs. Refer to slides 7 & 16 below. It's all about getting that cargo into the cell's nucleus, reach its target and having a therapeutic effect without causing toxicity. Note, there's still additional high throughput screening to take place right up until February 2019 and that's what I'm looking forward to.
https://www.asx.com.au/asxpdf/20171106/pdf/43nzyrs9jfjs43.pdf
Tony
TAT peptides can get into the nucleus of the cell, but only at...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.24 |
Change
0.040(3.33%) |
Mkt cap ! $723.2M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.24 | $1.19 | $1.500M | 1.241M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 204320 | $1.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 4333 | 2 |
View Market Depth
| Last trade - 16.11pm 24/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |